STAT3 activation in HER2‐positive breast cancers: Analysis of data from a large prospective trial. Issue 6 (23rd November 2020)

• Record Type: Journal Article
• Authors: Sonnenblick, Amir; Agbor‐tarh, Dominique; de Azambuja, Evandro; Hultsch, Susanne; Izquierdo, Miguel; Liu, Minetta; Pruneri, Giancarlo; Harbeck, Nadia; Piccart, Martine; Moreno‐Aspita, Alvaro; Granit, Roy Zvi; Rouas, Ghizlane; Fahoum, Ibrahim; Sotiriou, Christos
• Is Part Of: International journal of cancer. Volume 148:Issue 6(2021)
• Page Start: 1529
• Page End: 1535
• Publication Date: 2020-11-23
• Subjects: ALTTO -- breast cancer -- estrogen receptor -- HER2 -- STAT3; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.33385
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract: The JAK/STAT3 signaling pathway may be aberrantly activated and have various and conflicting roles in breast cancer. The current study explored prognostic implications of activated STAT3 in human epidermal growth factor receptor 2 (HER2)‐positive primary breast cancers in the context of a large prospective study (ALTTO). Activated STAT3 was determined by immunohistochemical analysis of STAT3 phosphorylation (Y705) performed on the primary tumors. This analysis evaluated whether patients with activated STAT3 had disease‐free survival (DFS) and overall survival (OS) different from patients without activated STAT3. A total of 5694 patients out of the 8381 patients enrolled in ALTTO were included in this analysis (67.9%), and 2634 of them (46%) had evidence of STAT3 activation (minimum tumor Allred score ≥2). The median follow‐up was 6.93 years (6.85‐6.97 years), at the end of which 1035 (18.18%) and 520 (9.13%) patients experienced DFS and OS events, respectively. Patients with STAT3 activation experienced improved DFS compared to those without it (multivariable hazard ratio [HR], 0.84; 95% confidence interval [CI] 0.74‐0.95; P = .006). There were no group differences in OS (multivariable HR, 0.92; 95% CI 0.78‐1.10; P = .37). This effect was limited to ER‐positive tumors. In conclusion, these findings support the role of STAT3 activation as a marker of favorable outcome in ER‐positive/HER2‐positive breast cancer patients. What's new?: The JAK/STAT3 signaling pathway is suspected of influencing tumor progression, with effects on tumor cell proliferation and survival. However, in breast cancer, evidence suggests that STAT3 in particular may have various and conflicting effects. In the present study, the prognostic implications of activated STAT3 were investigated in patients with HER2‐positive primary breast cancer. In patients with estrogen receptor (ER)‐positive/HER2‐positive tumors, STAT3 activation was associated with better disease‐free survival compared to patients without activated STAT3. No differences were detected in overall survival. The findings suggest that STAT3 activation is indicative of superior outcome in ER‐positive/HER2‐positive patients.